Testosterone Screening in Military: Evidence Gap Analysis

The Pentagon's Testosterone Screening Proposal: Where's the Evidence?

In late 2024, the Department of Defense announced plans for widespread testosterone screening in military personnel. The proposal has triggered legitimate pushback from endocrinologists and sports medicine physicians—not because testosterone matters (it does), but because the evidence supporting population-wide screening remains sparse.

This matters. Screening healthy asymptomatic populations differs fundamentally from targeted assessment in symptomatic individuals. Understanding that distinction requires knowing how testosterone fits into the endocrine axis, what the labs actually mean, and which patients genuinely benefit from intervention.

The Endocrine Reality: Testosterone Is Context-Dependent

Testosterone doesn't exist in isolation. It operates within the hypothalamic-pituitary-gonadal (HPG) axis—a feedback loop involving:

• GnRH (gonadotropin-releasing hormone) from the hypothalamus
• LH (luteinizing hormone) and FSH (follicle-stimulating hormone) from the pituitary
• Testosterone and estradiol from the gonads
• Negative feedback that suppresses GnRH and LH when testosterone rises

This system is exquisitely sensitive to training stress, sleep debt, caloric deficit, and psychological stressors—all endemic to military life. A single testosterone measurement in a fatigued soldier may reflect acute suppression rather than hypogonadism. Population screening without understanding context generates false positives and unnecessary treatment.

Reading the Labs: What a Testosterone Panel Actually Tells You

A complete testosterone assessment includes:

Total Testosterone (reference range typically 300–1000 ng/dL):

• Measures all testosterone: bound to SHBG, bound to albumin, and free
• Affected by SHBG levels (which rise with estrogen, thyroid hormone, and certain medications)
• Less sensitive for detecting true hypogonadism when SHBG is elevated

Free Testosterone (reference range typically 8–25 pg/mL):

• The biologically active fraction
• Better marker of clinical hypogonadism
• More stable across metabolic states

LH and FSH:

• Distinguish central (low LH/FSH) from primary (high LH/FSH) hypogonadism
• Critical for determining whether the pituitary-testicular axis is intact
• Omitting these renders testosterone interpretation incomplete

Estradiol (reference range typically 10–40 pg/mL in males):

• Produced via aromatization of testosterone
• Suppresses GnRH when elevated
• Rising estradiol with rising testosterone suggests secondary hypogonadism (the pituitary is self-suppressing via feedback)

SHBG (sex hormone-binding globulin, range 10–70 nmol/L):

• Determines how much testosterone is "available" at tissue level
• Elevated SHBG (from thyroid hormone, estrogen) reduces free testosterone despite normal total testosterone

The Screening vs. Diagnosis Problem

The medical literature on testosterone screening in asymptomatic men is unambiguous: routine screening is not recommended by the Endocrine Society, American Academy of Family Physicians, or U.S. Preventive Services Task Force.

Why? Because:

1. No intervention trial shows mortality or morbidity benefit from treating asymptomatic low testosterone
2. Testosterone treatment carries real risks: erythrocytosis (elevated hemoglobin/hematocrit), hypertension, sleep apnea progression, hepatic effects, gynecomastia from excess aromatization
3. Baseline testosterone varies 2–3 fold across individuals due to genetics, circadian rhythm, recent training load, and sleep
4. A single low measurement misses the dynamic context—the same soldier with 280 ng/dL after a brutal training week might return to 520 ng/dL after a recovery week

Military readiness is not synonymous with testosterone levels. Screening soldiers without symptoms or laboratory signs of true hypogonadism (low free testosterone + elevated LH indicating primary testicular failure) overtreatment and exposes personnel to unnecessary pharmacological risk.

Who Should Be Tested?

Targeted assessment makes sense in symptomatic men:

• Persistent fatigue, depression, or loss of libido unresponsive to sleep and stress management
• Unexplained decline in strength or athletic performance over weeks to months
• Gynecomastia or sexual dysfunction
• Metabolic syndrome or insulin resistance unresponsive to lifestyle intervention

These individuals warrant:

1. Morning total and free testosterone (testosterone peaks in early morning)
2. LH, FSH, prolactin (to map the axis)
3. Estradiol and SHBG (to understand the metabolic context)
4. TSH, free T3, free T4 (thyroid suppresses testosterone signaling)
5. Cortisol, DHEA-S (chronic stress suppresses LH via CRH)
6. Lipid panel, fasting glucose, HbA1c (metabolic dysfunction impairs testosterone production)

A comprehensive panel identifies root causes—often correctable through sleep, training programming, nutrition, or supplements like magnesium glycinate, zinc, and vitamin D3—before testosterone therapy.

The Supplement Approach: Optimizing the Axis First

For soldiers with borderline low testosterone and no primary testicular pathology, supporting the HPG axis with evidence-based supplements can restore normal function:

• Magnesium glycinate: 400–500 mg daily. Magnesium is a GnRH agonist and reduces cortisol. Glycine binds GABA-A receptors, enhancing sleep quality and suppressing nighttime cortisol surge
• Zinc: 25–30 mg daily. Cofactor for 17β-HSD (the enzyme that converts androstenedione to testosterone). Deficiency is common in high-stress populations
• Vitamin D3 + K2: 4,000 IU D3 daily + 180 mcg MK7. Vitamin D upregulates LH receptors on Leydig cells; K2 enhances osteocalcin-mediated metabolic signaling
• NAC (N-acetylcysteine): 600–1,200 mg daily. Raises intracellular glutathione, reducing oxidative stress in testicular tissue
• Creatine monohydrate: 5 g daily. Increases ATP availability for testosterone synthesis; also supports CNS recovery
• Omega-3: 2–3 g EPA+DHA daily. Improves membrane fluidity in Leydig cells, enhancing testosterone production

These interventions address axis dysfunction without pharmacological risk—and they work best in individuals with intact pituitary-testicular physiology (normal LH/FSH).

Bottom Line

The Pentagon's proposal to screen asymptomatic military personnel for low testosterone reflects good intentions but weak evidence. Testosterone matters for readiness, but context matters more. A single low lab value in a fatigued, stressed soldier reflects the endocrine system working as designed—suppressing reproduction under threat.

Better approach: targeted assessment in symptomatic soldiers, comprehensive endocrine and metabolic evaluation to identify root causes, and aggressive non-pharmacological optimization (sleep, training periodization, micronutrient repletion) before considering exogenous testosterone.

Population screening treats testosterone as a number to chase rather than a hormone to understand.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.